Oncolytic Immunotherapy

被引：11
|
作者：
Hennessy, Morgan L. [1 ]
Bommareddy, Praveen K. [2 ]
Boland, Genevieve [1 ]
Kaufman, Howard L. [1 ,3 ]
机构：
[1] Massachusetts Gen Hosp, Div Surg Oncol, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA
[2] Rutgers State Univ, Sch Grad Studies, Grad Sch Biomed Sci, 195 Little Albany St, New Brunswick, NJ 08901 USA
[3] Replimune Inc, Woburn, MA 01801 USA
来源：
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2019年 / 28卷 / 03期
关键词：
Cancer; Immunogenic cell death; Immunotherapy; Intratumoral; Oncolytic virus; Treatment; PEXA-VEC JX-594; TALIMOGENE LAHERPAREPVEC; LENTIGO MALIGNA; OPEN-LABEL; CANCER; VIRUS; TRIAL; 1ST; IMIQUIMOD; MELANOMA;
D O I：
10.1016/j.soc.2019.02.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Oncolytic viruses are naturally occurring, or genetically engineered viruses that can be administered via intralesional injections or intravenously to induce cell death in tumor cells and activate antitumor immune responses. This review summarizes several oncolytic viruses in preclinical and clinical trials, describes challenges in clinical implementation, and important areas of future investigation.
引用
收藏
页码：419 / +
页数：13
相关论文
共 50 条
  • [21] Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
    Liikanen, Ilkka
    Koski, Anniina
    Merisalo-Soikkeli, Maiju
    Hemminki, Otto
    Oksanen, Minna
    Kairemo, Kalevi
    Joensuu, Timo
    Kanerva, Anna
    Hemminki, Akseli
    ONCOIMMUNOLOGY, 2015, 4 (03): : 1 - 13
  • [22] Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
    Rahman, Masmudur M.
    McFadden, Grant
    CANCERS, 2021, 13 (21)
  • [23] Interleukin-12-expressing oncolytic virus: A promising strategy for cancer immunotherapy
    Alkayyal, Almohanad A.
    Mahmoud, Ahmad B.
    Auer, Rebecca C.
    JOURNAL OF TAIBAH UNIVERSITY MEDICAL SCIENCES, 2016, 11 (03): : 187 - 193
  • [24] Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
    Ziogas, Dimitrios C.
    Martinos, Anastasios
    Petsiou, Dioni-Pinelopi
    Anastasopoulou, Amalia
    Gogas, Helen
    CANCERS, 2022, 14 (12)
  • [25] Immune System, Friend or Foe of Oncolytic Virotherapy?
    Finley, Anna C.
    Dey, Mahua
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [26] Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy
    Robilotti, Elizabeth
    Zeitouni, Nathalie C.
    Orloff, Marlana
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
  • [27] Neutrophils in oncolytic virus immunotherapy
    Zhou, Danya
    Zhang, Chenglin
    Sun, Jingyi
    Yuan, Ming
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [28] Oncolytic Viruses in Cancer Immunotherapy
    Li, Xiao
    Cheng, Zhongping
    ADVANCED THERAPEUTICS, 2024, 7 (07)
  • [29] Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
    Wang, Xianwang
    Shen, Yihua
    Wan, Xingxia
    Hu, Xiaoqing
    Cai, Wen-Qi
    Wu, Zijun
    Xin, Qiang
    Liu, Xiaoqing
    Gui, Jingang
    Xin, Hong-Yi
    Xin, Hong-Wu
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [30] CD8+ T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy
    Pourchet, Aldo
    Fuhrmann, Steven R.
    Pilones, Karsten A.
    Demaria, Sandra
    Frey, Alan B.
    Mulvey, Matthew
    Mohr, Ian
    EBIOMEDICINE, 2016, 5 : 59 - 67
12345